12 research outputs found
Inhibition of Fibroblast Growth Factor Receptor Signaling Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice
Detection of methicillin-resistant Staphylococcus aureus in dairy cow farms
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most common pathogens causing nosocomial infections worldwide. Animal-associated MRSA hazard has been recently identified, but less information is currently available regarding MRSA in cattle. The aim of this study was to estimate the presence of MRSA in samples of bulk milk, environmental dust, conjunctival and nasal swabs of workers obtained from thirty dairy cow farms. A total of 200 S. aureus strains were identified using phenotypic and molecular approaches. Three other species (Staphylococcus epidermidis, Staphylococcus xylosus and Staphylococcus saprophyticus) were found. In five S. aureus strains isolated from environmental dust and one S. epidermidis strain derived from human samples, mecA gene was detected showing a specific fragment at 527 bp. Moreover, 66 S. aureus strains were distinguished by susceptibility to 15 antimicrobial agents. The highest resistance profile was ascribed to ampicillin, amoxicillin and penicillin G, both in workers and bulk milk samples. Generally, a multiple resistance to 4 up to 10 antibiotics was detected. S. aureus mecA+ strains and S. epidermidis mecA+ strain showed multiple resistance to 13 and 11 antibiotics, respectively. The obtained results suggested that the low number of MRSA strains, probably of human origin, was due to the appropriate hygienic practices adopted by the dairy cow farm
ENHANCING EXPRESSION OF PRO-APOPTOTIC FACTORS THROUGH INHIBITION OF HDACS DRIVES P53-INDEPENDENT SYNERGY WITH VENETOCLAX FOR THE TREATMENT OF AML
TARGETING MULTIDRUG RESISTANCE PROTEIN 1 (MDR1) POTENTIATES SMAC-MIMETIC THERAPY TO KILL LEUKEMIC STEM CELLS AND OVERCOME RESISTANCE IN ACUTE MYELOID LEUKEMIA
Combining BH3-Mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
Improving outcomes in acute myeloid leukemia (AML) remains a major clinical challenge. Overexpression of pro-survival BCL-2 family members rendering transformed cells resistant to cytotoxic drugs is a common theme in cancer. Targeting BCL-2 with the BH3-mimetic venetoclax is active in AML when combined with low-dose chemotherapy or hypomethylating agents. We now report the pre-clinical anti-leukemic efficacy of a novel BCL-2 inhibitor S55746, which demonstrates synergistic pro-apoptotic activity in combination with the MCL1 inhibitor S63845. Activity of the combination was caspase and BAX/BAK dependent, superior to combination with standard cytotoxic AML drugs and active against a broad spectrum of poor risk genotypes, including primary samples from patients with chemoresistant AML. Co-targeting BCL-2 and MCL1 was more effective against leukemic, compared to normal hematopoietic progenitors, suggesting a therapeutic window of activity. Finally, S55746 combined with S63845 prolonged survival in xenograft models of AML and suppressed patient-derived leukemia but not normal hematopoietic cells in bone marrow of engrafted mice. In conclusion, a dual BH3-mimetic approach is feasible, highly synergistic, and active in diverse models of human AML. This approach has strong clinical potential to rapidly suppress leukemia, with reduced toxicity to normal hematopoietic precursors compared to chemotherapy
Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death
International audienceAbstract Cancer cell metabolism is increasingly recognized as providing an exciting therapeutic opportunity. However, a drug that directly couples targeting of a metabolic dependency with the induction of cell death in cancer cells has largely remained elusive. Here we report that the drug-like small-molecule ironomycin reduces the mitochondrial iron load, resulting in the potent disruption of mitochondrial metabolism. Ironomycin promotes the recruitment and activation of BAX/BAK, but the resulting mitochondrial outer membrane permeabilization (MOMP) does not lead to potent activation of the apoptotic caspases, nor is the ensuing cell death prevented by inhibiting the previously established pathways of programmed cell death. Consistent with the fact that ironomycin and BH3 mimetics induce MOMP through independent nonredundant pathways, we find that ironomycin exhibits marked in vitro and in vivo synergy with venetoclax and overcomes venetoclax resistance in primary patient samples. Significance: Ironomycin couples targeting of cellular metabolism with cell death by reducing mitochondrial iron, resulting in the alteration of mitochondrial metabolism and the activation of BAX/BAK. Ironomycin induces MOMP through a different mechanism to BH3 mimetics, and consequently combination therapy has marked synergy in cancers such as acute myeloid leukemia. This article is highlighted in the In This Issue feature, p. 58
Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription
Resistance to cell death is a hallmark of cancer and renders transformed cells resistant to multiple apoptotic triggers. The Bcl-2 family member, Mcl-1, is a key driver of cell survival in diverse cancers, including acute myeloid leukemia (AML). A screen for compounds that downregulate Mcl-1 identified the kinase inhibitor, PIK-75, which demonstrates marked proapoptotic activity against a panel of cytogenetically diverse primary human AML patient samples. We show that PIK-75 transiently blocks Cdk7/9, leading to transcriptional suppression of MCL-1, rapid loss of Mcl-1 protein, and alleviation of its inhibition of proapoptotic Bak. PIK-75 also targets the p110α isoform of PI3K, which leads to a loss of association between Bcl-xL and Bak. The simultaneous loss of Mcl-1 and Bcl-xL association with Bak leads to rapid apoptosis of AML cells. Concordantly, low Bak expression in AML confers resistance to PIK-75–mediated killing. On the other hand, the induction of apoptosis by PIK-75 did not require the expression of the BH3 proteins Bim, Bid, Bad, Noxa, or Puma. PIK-75 significantly reduced leukemia burden and increased the survival of mice engrafted with human AML without inducing overt toxicity. Future efforts to cotarget PI3K and Cdk9 with drugs such as PIK-75 in AML are warranted
AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies
Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia
ISSN:1934-5909ISSN:1875-977